Rebuttal: palivizumab for the prevention of respiratory syncytial virus infection. Journal Articles
- Overview
- Research
- Additional Document Info
- View All
Overview
status
publication date
- October 2010
has subject area
- 1117 Public Health and Health Services (FoR)
- Antibodies, Monoclonal, Humanized (MeSH)
- Antiviral Agents (MeSH)
- General & Internal Medicine (Science Metrix)
- Humans (MeSH)
- Respiratory Syncytial Virus Infections (MeSH)
published in
- Canadian Family Physician Journal